Catalog No.
RHE35201
Species reactivity
Human, Mouse, Rat, Rabbit
Host species
Mouse
Isotype
IgG2a
Clonality
Monoclonal
Tested applications
FCM: 1:200-1:400, IF: 1:200-1:1000, IHC: 1:200-1:1000
Target
Phosphoinositide-3-kinase catalytic alpha polypeptide, PIK3CA, PtdIns-3-kinase subunit p110-alpha, PI3-kinase subunit alpha, p110alpha, Serine/threonine protein kinase PIK3CA, PI3K-alpha, Phosphoinositide 3-kinase alpha, Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform, PI3Kalpha, PtdIns-3-kinase subunit alpha, Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P42336
Applications
FCM, IF, IHC
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% Sodium Azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
R3K76
ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial., PMID:40512191
Molecular and clinicopathological characteristics of invasive breast cancers with HER2-ultralow expression., PMID:40379141
Combined Chemotherapy-Immunotherapy for Advanced Biliary Tract Cancer (BTC): A Clinical, Genomic, and Biomarker Analysis., PMID:40167580
Novel Estrogen Receptor - Targeted Therapies in Hormone-Receptor Positive Breast Cancer., PMID:40163189
Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial., PMID:40107157
Treatment of extended RAS/BRAF wild-type metastatic colorectal cancer with anti-EGFR antibody combinations., PMID:40097366
Atezolizumab and Bevacizumab prior to liver transplantation in hepatic angiosarcoma mimicking hepatocellular carcinoma., PMID:40083292
Prognostic Value of Trop-2 Expression in Nonmetastatic Triple-Negative Breast Cancer and Correlation With Emerging Biomarkers., PMID:40059728
Elucidating the pharmacological foundations and mechanisms of the Sihai Shuyu formula in treating Graves' disease through integrated serum metabolomics and network pharmacology with molecular docking techniques., PMID:39950029
Case report: Chemotherapy plus sintilimab for the treatment of gastroesophageal junction hepatoid adenocarcinoma with liver metastasis: a case study with literature review., PMID:39931054
Immunolipid magnetic bead-based circulating tumor cell sorting: a novel approach for pathological staging of colorectal cancer., PMID:39927117
A neoantigen vaccine generates antitumour immunity in renal cell carcinoma., PMID:39910301
Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): efficacy, safety and biomarker analysis of a prospective, multicentre, response-adapted study., PMID:39875376
Efficacy of ramucirumab combined with erlotinib or osimertinib in untreated EGFR-mutated NSCLC patients with asymptomatic brain metastases: insights from molecular biomarkers in the RELAY-brain trial., PMID:39847172
Impacts of genomic alterations on the efficacy of HER2-targeted antibody-drug conjugates in patients with metastatic breast cancer., PMID:39806366
Targeted Sequencing of HER2-Positive Breast Cancer Mutations Revealed a Potential Association between PIK3CA and Trastuzumab Resistance., PMID:39611930
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01., PMID:39587050
Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer., PMID:39513959
Alpelisib and Immunotherapy: A Promising Combination for Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck., PMID:39376013
Pyrotinib and trastuzumab combination treatment synergistically overcomes HER2 dependency in HER2-positive breast cancer: insights from the PHILA trial., PMID:39368454
Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab., PMID:39269823
Impact of PIK3CA gain and PTEN loss on mantle cell lymphoma biology and sensitivity to targeted therapies., PMID:39158100
Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial., PMID:39088783
An ultra-sensitive and rapid immunosensor for the onsite detection of circulating tumor DNA in breast cancer., PMID:39070168
Clinicopathological, molecular, and prognostic features of colorectal carcinomas with KRAS c.34G>T (p.G12C) mutation., PMID:39039804
Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma., PMID:38963640
PD-L1 and nectin-4 expression and genomic characterization of bladder cancer with divergent differentiation., PMID:38959291
Multi-omic analysis of dysregulated pathways in triple negative breast cancer., PMID:38899578
HER2-Low Luminal Breast Carcinoma Is Not a Homogenous Clinicopathological and Molecular Entity., PMID:38893129
Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer., PMID:38833970
A phase II study of cabozantinib and pembrolizumab in advanced gastric/gastroesophageal adenocarcinomas resistant or refractory to immune checkpoint inhibitors., PMID:38823034
Long-term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study., PMID:38741375
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy., PMID:38704093
Monitoring ctDNA RAS Mutational Status in Metastatic Colorectal Cancer: A Trial Protocol of RAS-trace and RAS-trace-2 Studies., PMID:38689780
Comprehensive characterization of immunogenic cell death in acute myeloid leukemia revealing the association with prognosis and tumor immune microenvironment., PMID:38671491
Therapeutic Advances and Challenges for the Management of HPV-Associated Oropharyngeal Cancer., PMID:38612819
Comprehensive characterization of genomic features and clinical outcomes following targeted therapy and secondary cytoreductive surgery in OCCC: a single center experience., PMID:38606821
Establishment of a human ovarian clear cell carcinoma cell line mutant in PIK3CB but not PIK3CA., PMID:38573494
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer., PMID:38513188
Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study., PMID:38458039
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial., PMID:38406172
Clinical sequencing defines the somatic and germline mutation landscapes of Chinese HER2-Low Breast Cancer., PMID:38403109
Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada., PMID:38400668
mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation., PMID:38344201
Targeting PI3K/AKT/mTOR and MAPK Signaling Pathways in Gastric Cancer., PMID:38339127
Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212)., PMID:38289994
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146., PMID:38242717
Vaccine antibodies against a synthetic epidermal growth factor variant enhance the antitumor effects of inhibitors targeting the MAPK/ERK and PI3K/Akt pathways., PMID:38183801
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial., PMID:38177853
Integrated Molecular Characterization of HER2-Low Breast Cancer Using Next Generation Sequencing (NGS)., PMID:38137385
For research use only. Not for human or drug use.
